| Literature DB >> 23721513 |
Chuanbing Zang1, Jan Eucker, Hongyu Liu, Annekatrin Coordes, Minoo Lenarz, Kurt Possinger, Christian Wilfried Scholz.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most frequent aggressive lymphoma, with a great demand for novel treatments for relapsing and refractory disease. Constitutive activation of the phosphatidyl-inositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway is often detected in this lymphoma. Inhibition of this signaling cascade with the pan-class I PI3K inhibitor NVP-BKM120 decreased cell proliferation and increased apoptotic cell death. DLBCL proliferation was further decreased if NVP-BKM120-induced autophagy was blocked. Treatment with NVP-BKM120 was associated with an increase of the pro-apoptotic BH3-only proteins Puma and Bim and down-regulation of the anti-apoptotic Bcl-xL and Mcl-1. Translation of Bcl-xL and Mcl-1 is facilitated by cap-dependent mRNA translation, a process that was partially inhibited by NVP-BKM120. Overall, we demonstrated here the potential of NVP-BKM120 for the treatment of DLBCL.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23721513 DOI: 10.3109/10428194.2013.806800
Source DB: PubMed Journal: Leuk Lymphoma ISSN: 1026-8022